Polycythaemia vera is a chronic malignant disease of the haematopoietic system and is treated with interferon-alpha-based drugs, in most cases with long-lasting success. However, in some cases this ...

The evolving treatment landscape in polycythemia vera (PV) is shifting from a focus on hematocrit control to a more ...

The British Society for Haematology has released a new updated guideline that offers practical guidance for the management of specific situations and complications of polycythemia vera and outlines ...

The evaluation committee considered evidence submitted by Novartis Pharmaceuticals, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the ...

VIENNA--(BUSINESS WIRE)--AOP Health announced the final results on Ropeginterferon alfa-2b in patients with Polycythaemia Vera (PV) from its CONTINUATION-PV study in an oral presentation at the ...

VIENNA--(BUSINESS WIRE)--AOP Health announced new results on ropeginterferon alfa-2b (BESREMi®) from its clinical study CONTINUATION-PV in patients with polycythaemia vera (PV), a rare blood cancer.

Takeda's $300 million wager on Protagonist Therapeutics' rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off. The first phase 3 trial of the injectable hepcidin mimetic, ...

Following review of Ruxolitinib in polycythaemia vera, patients complain of fatigue less frequently and have a better quality of life. The study design makes interpretation of the results difficult, ...

With the ink barely dry on a deal to buy Kelonia, Lilly has signed a $2.3bn deal to acquire Ajax Therapeutics and its JAK2 blood cancer therapy. A phase 3 win suggests Takeda's $300m wager on ...